20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
ABUSE-DETERRENT DOSAGE FORMS
#2102PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR PREVENTING, INHIBITING OR TREATING NAUSEA AND VOMITING
#2103Treating pain in patients with hepatic impairment
#2104Methods and compositions for treatment of epithelial wounds
#2105PROCESS FOR PREPARING OXYCODONE COMPOSITIONS
#2106Process for preparing oxycodone compositions
#2107IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS
#2108Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
#2109TREATMENTS FOR ALZHEIMER'S RELATED DISEASES AND DISORDERS
#2110Pegylated Opioids with Low Potential for Abuse
#2111Tamper resistant controlled release dosage forms
#2112Encased tamper resistant controlled release dosage forms
#2113Tamper resistant controlled release dosage forms
#2114Opioid Antagonist Formulations
#2115Method and compositions for dissolving or solubilizing therapeutic agents
#2116Dosage forms for administering combinations of drugs
#2117GASTRIC RETENTIVE EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS
#2118Method for treating hypertension
#2119Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
#2120Buprenorphine-wafer for drug substitution therapy
#2121Buprenorphine-wafer for drug substitution therapy
#2122Transdermal patch comprising a ropivacaine formulation
#2123Oral composition comprising a cooling agent
#2124METHOD FOR EXTRACTION AND CONCENTRATION OF ALKALOIDS USING DIMETHYL ETHER
#2125Controlled release hydrocodone formulations
#2126Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#2127Pharmaceutical Formulation
#2128MICRONIZED OPIOID COMPOSITIONS, FORMULATIONS AND DOSAGE FORMS AND METHODS OF MAKING SAME
#2129Methods of increasing satellite cell proliferation with kinase inhibitors
#2130Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
#2131PHARMACEUTICAL COMPOSITION OF BUPROPION AND NALTREXONE
#2132PHARMACEUTICAL COMPOSITION OF BUPROPION AND NALTREXONE
#2133Process of preparing low ABUK oxymorphone hydrochloride
#2134Base composition for tape agent
#2135COMPOSITIONS AND METHODS USING FLUMAZENIL WITH OPIOID ANALGESICS FOR TREATING PAIN AND/OR ADDICTION, AND WITH DIVERSION AND/OR OVERDOSE MITIGATION
#2136ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
#2137GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
#2138Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
#2139Extruded Immediate Release Abuse Deterrent Pill
#2140Abuse-deterrent opioids
#2141Bupropion as a modulator of drug activity
#2142Transdermal patch
#2143SUBLINGUAL NALOXONE SPRAY
#2144METHOD FOR MANUFACTURING AN INGESTIBLE FILM, APPARATUS FOR MANUFACTURING AN INGESTIBLE FILM, INGESTIBLE FILM AND PHARMACEUTICAL DOSAGE FORM COMPRISING THE SAME
#2145Oral drug delivery system
#2146Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
#2147METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
#2148Methods of delivering pharmaceutical agents
#2149Drug combinations and uses in treating a coughing condition
#2150Drug combinations and uses in treating a coughing condition
#2151COMBINATION COMPOSITION COMPRISING OXYCODONE AND ACETAMINOPHEN FOR RAPID ONSET AND EXTENDED DURATION OF ANALGESIA
#2152INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B)
#2153Crush resistant delayed-release dosage forms
#2154Compositions comprising buprenorphine
#2155ABUSE-PROOFED ORAL DOSAGE FORM
#2156Nasal drug products and methods of their use
#2157Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
#2158SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#2159TREATMENT FOR COLLAPSING TRACHEA
#2160Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
#2161Oral Pharmaceutical Compositions of Buprenorphine and Another Opioid Receptor Agonist
#21628-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
#2163Tamper-resistant pharmaceutical dosage forms and process for making same
#2164TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE
#2165PROCESS FOR PREPARING OXYCODONE DOCAGE FORM
#2166METHODS OF TREATING PAIN
#2167OXYCODONE DOSAGE FORMS
#2168Morphine formulations
#2169Method of producing uniform buprenorphine-containing formulations
#2170ABUSE-PROOFED ORAL DOSAGE FORM
#2171Nanoparticles and methods of producing the same
#2172Nasal drug products and methods of their use
#2173Modified release formulations containing drug-ion exchange resin complexes
#2174SUSTAINED RELEASE FORMULATION OF NALTREXONE
#2175Controlled release hydrocodone formulations
#2176Controlled release hydrocodone formulations
#2177COMBINATIONS OF OPIOID/TLR4 ANTAGONIST AND A CYCLOOXYGENASE (COX) INHIBITOR FOR USE IN THE TREATMENT OF PAIN
#2178SUSTAINED RELEASE FORMULATION OF NALTREXONE
#2179TRANSORAL DOSAGE FORMS COMPRISING SUFENTANIL AND NALOXONE
#2180Encased tamper resistant controlled release dosage forms
#2181Pharmaceutical Formulation Containing Gelling Agent
#2182Pharmaceutical formulation containing gelling agent
#2183Controlled release hydrocodone formulations
#2184Pharmaceutical Formulation Containing Gelling Agent
#2185Method of treating dyskinesia
#2186Pharmaceutical formulation containing gelling agent
#2187Pharmaceutical formulation containing gelling agent
#2188Pharmaceutical formulation containing gelling agent
#2189Pharmaceutical formulation containing gelling agent
#2190Abuse-resistant controlled-release opioid dosage form
#2191Abuse-resistant controlled-release opioid dosage form
#2192Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
#2193NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS
#2194Sublingual films
#2195Pharmaceutical formulation containing gelling agent
#2196Controlled release hydrocodone formulations
#2197Pharmaceutical Formulation Containing Gelling Agent
#2198Pharmaceutical Formulation Containing Gelling Agent
#2199Pharmaceutical formulation containing gelling agent
#2200Controlled release hydrocodone formulations
#2201Enhanced stability of novel liquid compositions
#2202Pharmaceutical formulation containing gelling agent
#2203PATCH DEVICES, METHODS AND APPARATUS FOR FORMING, AND TESTING PHARMACEUTICAL AGENT DELIVERY PATCH DEVICES
#2204Vaporized medicants and methods of use
#2205Methods of providing weight loss therapy in patients with major depression
#2206COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
#2207PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
#2208Tamper Resistant Oral Dosage Forms
#2209Polymorphic forms of naltrexone
#2210INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#2211Immediate release pharmaceutical compositions comprising oxycodone and naloxone
#2212Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#2213EXTENDED RELEASE HYDROCODONE ACETAMINOPHEN AND RELATED METHODS AND USES THEREOF
#2214Diversion-resistant opioid formulations
#2215OXYMORPHONE CONTROLLED RELEASE COMPOSITIONS
#2216Orvinol and thevinol derivatives useful in the treatment of anxiety or a compulsive disorder
#2217Oral pharmaceutical dosage forms
#2218Injectable delivery of microparticles and compositions therefor
#2219Oligomer-opioid agonist conjugates
#2220ADENINE DERIVATIVES HAVING IMMUNOMODULATING ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY
#2221Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
#2222SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS
#2223Injectable flowable composition comprising buprenorphine
#2224Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
#2225Transdermal delivery system comprising buprenorphine
#2226Methods of preparing tamper resistant solid oral dosage forms
#2227CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
#2228Dihydroetorphines and their preparation
#2229Peripheral opioid receptor antagonists and uses thereof
#2230Sublingual and buccal film compositions
#2231Stable oral solutions for combined API
#2232Tamper resistant dosage form comprising inorganic salt
#2233Treatment of cancer with naltrexone
#2234Pharmaceutical compositions
#2235Treating pain in patients with hepatic impairment
#2236Treating pain in patients with hepatic impairment
#2237Treating pain in patients with hepatic impairment
#2238Extended Release Abuse Deterrent Liquid Fill Dosage Form
#2239Dihydroetorphine for the provision of pain relief and anaesthesia
#2240Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#2241Abuse Deterrent Immediate Release Formulation
#2242Sublingual apomorphine
#2243PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
#2244USE OF BINDERS FOR MANUFACTURING STORAGE STABLE FORMULATIONS
#2245ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#2246TREATMENT OF NEUROLOGICAL AND OTHER DISORDERS
#2247Sublingual apomorphine
#2248Sublingual apomorphine
#2249Selective Opioid Compounds
#22504:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
#2251Sublingual apomorphine
#2252ABUSE-PROOFED DOSAGE FORM
#2253Systems and Methods for Attenuating Opioid-Induced Euphoria
#2254Abuse resistant pharmaceutical compositions
#2255Abuse resistant pharmaceutical compositions
#2256Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
#2257Orally administrable compositions and methods of deterring abuse by intranasal administration
#2258Pharmaceutical compositions resistant to abuse
#2259Abuse-deterrent pharmaceutical compositions of opioids and other drugs
#2260Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
#2261SEMI-SOLID CHEWABLE DOSAGE FORM FOR OVER-THE-COUNTER MEDICATIONS AND METHOD FOR PRODUCING SAME
#2262Process for making controlled release medical implant products
#2263INTRATHECAL MULTIDRUG INFUSION FOR PAIN CONTROL
#2264Pharmaceutical Composition
#2265Nalmefene for Treatment of Patients with Anxiety Disorder
#2266Nalmefene for Treatment of Patients with Mood Disorder
#2267TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY FOR NEUROPATHIC CONDITIONS
#2268PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM
#2269Vaporized medicants and methods of use
#2270Deuterated morphine derivatives
#2271Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
#2272Method and dosage regimens for eliminating a chemical substance in blood
#2273OPIOID AGONIST/ANTAGONIST COMBINATIONS
#2274Methods for treating antipsychotic-induced weight gain
#2275Combinations of opioid/TLR4 antagonist and acetyl-para-aminophenol (APAP) for use in the treatment of pain
#2276COMPOSITIONS TO ALLEVIATE PRESYSTEMIC METABOLISM OF OPIOIDS
#2277Morphinan Derivatives for the Treatment of Drug Overdose
#2278Sustained Release Composition Comprising an Amine as Active Agent and a Salt of a Cyclic Organic Acid
#2279Pharmaceutical compositions
#2280ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#2281ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#2282Methods of treating pain or fever using pharmaceutically active acetaminophen dimers linked through phenolic hydroxyl groups
#2283Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
#2284Sublingual buprenorphine spray
#2285Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
#2286Compositions with a rheological modifier to reduce dissolution variability
#2287Use of buprenorphine dimer in the treatment of peripheral neuropathic pain
#2288Intranasal naloxone compositions and methods of making and using same
#2289Compositions with Thixotropy and Enhanced Dissolution Reproducibility and Stability
#2290Tamper resistant pharmaceutical formulations
#2291Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
#2292METHODS OF DIAGNOSING ENDOMETRIOSIS
#2293Cancer therapy
#2294Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
#2295Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
#2296Oxycodone formulations
#2297METHOD FOR DECREASING LOW DENSITY LIPID PROTEIN
#2298Pain Medicine Combination and Uses Thereof
#2299MEDICAL IMPLANT
#2300Compositions and methods for reducing overdose
#2301ABUSE-PROOFED DOSAGE FORM
#2302NON-MUCOADHESIVE FILM DOSAGE FORMS
#2303MEDICAL IMPLANT
#2304Devices and methods for delivering opioid antagonists including formulations for naloxone
#2305PHENYLEPHRINE FORMULATIONS WITH IMPROVED STABILITY
#2306Immediate release abuse deterrent liquid fill dosage form
#2307PHARMACEUTICAL COMPOUNDING KIT
#2308PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS
#2309Bupropion as a modulator of drug activity
#2310Abuse-resistant controlled-release opioid dosage form
#2311Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
#2312Sublingual naloxone spray
#2313TRANSDERMAL DELIVERY SYSTEM
#2314Buprenorphine nanoparticle composition and methods thereof
#2315CO-PACKAGED DRUG PRODUCTS
#2316Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
#2317Child Resistant Cover for Oral Dosage Forms
#2318Pharmaceutical Formulation Containing Gelling Agent
#2319Pharmaceutical formulation containing gelling agent
#2320Pharmaceutical Formulation Containing Gelling Agent
#2321Pharmaceutical Formulation Containing Gelling Agent
#2322Pharmaceutical Formulation Containing Gelling Agent
#2323Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
#2324Morphan and morphinan analogues, and methods of use
#2325Analgesic conjugates
#2326METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF THE PHYSIOLOGIC AGENTS TO TISSUE SURFACES
#2327Method for administering ω-conopeptide
#2328Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
#2329UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS
#2330Pharmaceutical Formulation Containing Gelling Agent
#2331Crush resistant delayed-release dosage forms
#2332Pharmaceutical formulation containing gelling agent
#2333Pharmaceutical formulation containing irritant
#2334Compositions and methods for weight loss in at risk patient populations
#2335PHARMACEUTICAL COMPOSITIONS INCORPORATING LOW-DOSE DRUGS
#2336Pharmaceutical products
#2337Oxidation-stabilized tamper-resistant dosage form
#2338TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE
#2339STABILITY OF HYDROMORPHONE HYDROCHLORIDE SOLUTIONS
#2340METHODS FOR TREATING PRURITUS
#2341USE OF SELECTIVE DELTA-OPIOID RECEPTOR ANTAGONISTS AND SPECIFIC SENSORY RECEPTOR LIGANDS
#2342Compositions and Methods of Reducing Sedation
#2343TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY
#2344Compositions and methods to promote bone formation
#2345Ketamine or dextromethorphan formulations and methods of use
#2346Treatments For Depression And Other Diseases With A Low Dose Agent
#2347Morphinan compounds
#2348Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#2349Treating pain in patients with hepatic impairment
#2350(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
#2351Use of amisulpride as an anti-emetic
#2352Diversion- and/or abuse-resistant compositions and methods for making the same
#2353Multiparticles safeguarded against ethanolic dose-dumping
#2354Tamper resistant dosage forms
#2355Tamper resistant dosage forms
#2356Tamper resistant dosage forms
#2357Tamper resistant dosage forms
#2358Tamper resistant dosage forms
#2359Substituted noribogaine
#2360Enteric combination therapy
#2361Pharmaceutical compositions
#2362PHARMACEUTICAL COMPOSITIONS
#2363Pharmaceutical compositions
#2364PHARMACEUTICAL COMPOSITIONS
#2365Pharmaceutical compositions
#2366Using palmitoylethanolamide in combination with opioids
#2367ORAL FORM, COMPRISING IMMEDIATE-RELEASE COATED PARTICLES OF AT LEAST ONE ACTIVE COMPOUND THAT ARE GRINDING-RESISTANT
#2368PHARMACEUTICAL PREPARATIONS
#2369Pharmaceutical compositions
#2370METHOD FOR INTRODUCING BIOLOGICALLY ACTIVE SUBSTANCES INTO THE BRAIN
#2371Buprenorphine-wafer for drug substitution therapy
#2372ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER
#2373Pharmaceutical compositions
#2374Process for improved opioid synthesis
#2375Immediate release composition resistant to abuse by intake of alcohol
#2376PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN ASSOCIATED WITH DYSMENORRHEA
#2377PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM
#2378ABUSE-PROOFED ORAL DOSAGE FORM
#2379Pharmaceutically active dimers linked through phenolic hydroxyl groups
#2380Buprenorphine dimer and its use in treatment of gastrointestinal disorders
#2381TRANSDERMAL DELIVERY SYSTEM
#2382Medications for deposition on biological surfaces
#2383Pharmaceutical compositions
#2384Diagnostic tools for charcot-marie-tooth disease
#2385Intranasal medication delivery device and method of use thereof
#2386Medicament delivery device for administration of opioid antagonists including formulations for naloxone
#2387Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
#2388Pharmaceutical composition having reduced abuse potential
#2389Intranasal medication delivery device and method of use thereof
#2390Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
#2391Intravenous administration of tramadol
#2392Pharmaceutical Compositions
#2393Pharmaceutical compositions
#2394PHARMACEUTICAL COMPOSITIONS
#2395Synthesis of (R)-N-methylnaltrexone
#2396Sedating and immobilizing non-domesticated mammals
#2397Crush resistant delayed-release dosage forms
#2398Solid salt form of α-6-mPEG-O-hydroxycodone as opioid agonists and uses thereof
#2399Pharmaceutical formulation containing gelling agent
#2400METHOD FOR TREATING PAIN WITH ASTER EXTRACT